酶赛生物, 斩获浙江省科技技术进步二等奖，宣布正式启动IPO！

Core Viewpoint - Enzyme Science is recognized for its innovative contributions to biomanufacturing, particularly in the development of chiral amines, and aims to lead advancements in synthetic biology and green manufacturing [2][3]. Group 1: Awards and Recognition - Enzyme Science's project on "Key Technology Innovation and Industrialization Demonstration of Biomanufacturing of Chiral Amines with Cyclic Structures" won the second prize of the 2024 Zhejiang Provincial Science and Technology Progress Award [2]. - The company has received multiple honors, including being recognized as a high-tech enterprise and a "little giant" in specialized and innovative sectors [3]. Group 2: Technological Innovations - The company utilizes protein crystallography and computational biology to reconstruct ancestral sequences and analyze the crystal structure of transaminases, enhancing enzyme stability, activity, and substrate universality [2]. - Enzyme Science has developed a "green biosynthesis - product precise separation - multi-category chiral amine large-scale manufacturing" technology system, achieving high-purity production of various chiral amines [2]. Group 3: Research and Development Efficiency - The establishment of the EnzyAI virtual computing platform has significantly improved R&D efficiency, allowing one person to achieve what previously required a team of five over several months [5]. - The number of new products developed annually has increased from two to over ten [5]. Group 4: Collaborations and Partnerships - Enzyme Science has formed partnerships with institutions like Shenzhen University of Technology to create a predictive and programmable intelligent biomanufacturing platform [5][7]. - The company is also collaborating with teams to explore marine extremophilic microbial enzyme resources and AI-assisted design [7]. Group 5: Commercialization and Market Reach - Enzyme Science has commercialized over 20 products across various sectors, including pharmaceutical intermediates and food additives, with expectations of doubling revenue this year [7]. - The company serves major global pharmaceutical firms such as AstraZeneca, Bayer, and Merck, contributing to significant medications for conditions like high cholesterol and diabetes [8]. Group 6: Future Plans and IPO - Enzyme Science plans to initiate an IPO in early 2026, with a Pre-IPO financing round aimed at expanding production capacity and enhancing cash flow, expecting a valuation exceeding 1.5 billion [8]. - The company aims to extend its applications beyond pharmaceuticals and food into sectors like new energy vehicles and textiles, contributing to carbon neutrality goals [8].